---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-424644"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-10-19T11:05:19+00:00"
generated_at: "2026-10-19T11:10:07.730285+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.87
calibrated_materiality_score: 0.87
confidence: "high"
source: SEC EDGAR
---

# EyePoint's LUCIA Phase 3 DURAVYU trial misses primary BCVA non-inferiority endpoint in wet AMD

## Summary
- LUCIA (475 patients) failed the primary endpoint of statistical non-inferiority in mean BCVA change vs on-label 2 mg aflibercept, despite demonstrating visual improvement.
- Key secondary endpoints met: 38% reduction in treatment burden (nominal p<0.0001), 52% of eyes supplement-free and 71% receiving zero or one supplement through Week 56.
- Favorable safety profile with redosing and strong anatomic control at Week 56, consistent with LUGANO (432 patients), which also missed its primary endpoint.
- EyePoint will complete additional analyses of LUCIA and pooled Phase 3 datasets to assess next steps for DURAVYU in wet AMD.
- DME program on track: pivotal COMO and CAPRI topline data expected Q4 2027; Phase 2 VERONA showed +7.1 letter BCVA gain and 73% supplement-free at Week 24.

## SEC filing metadata
- accession: 0001193125-26-424644
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-10-19T11:05:19+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.87
- calibrated_materiality_score: 0.87
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/0001193125-26-424644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526424644/eypt-20261019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-424644
- JSON: https://secwatch.observer/filing/0001193125-26-424644.json
- Plain text: https://secwatch.observer/filing/0001193125-26-424644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.